Mycophenolate Mofetil Shortage: What Providers and Prescribers Need to Know in 2026

Drug shortages are a persistent and growing challenge in U.S. healthcare, and mycophenolate mofetil (MMF) is among the medications with the most serious clinical consequences when supply fails. For prescribers managing post-transplant immunosuppression or treating autoimmune diseases, a shortage of this medication requires prompt, systematic action.

This guide reviews the 2026 shortage status, clinical risk stratification, therapeutic alternatives, and operational steps that transplant centers, rheumatology practices, and outpatient pharmacies should implement proactively.

Current Shortage Status: What Providers Need to Know

Mycophenolate mofetil capsules and tablets (250 mg capsules; 500 mg tablets) remain on the ASHP drug shortage list as of 2026. Multiple generic manufacturers have reported supply constraints, including Mylan, Sandoz, Hikma, Accord, Ascend, and Teva. Mycophenolate sodium delayed-release tablets (generic Myfortic equivalents) have also been affected, with Apotex and Major reporting back-orders.

In 2023, the End Drug Shortages Alliance — a collaboration among Vizient, ASHP, and the Children's Hospital Association — specifically identified mycophenolate mofetil as one of five essential medications at greatest risk of supply disruption following a major pharmaceutical plant closure. This served as an early warning that prescribers should take seriously.

As of early 2026, availability remains inconsistent. Some manufacturers have partial supply, some pharmacies are fully stocked, and others are completely out. This geographic and supplier patchwork demands proactive patient-level monitoring.

Why This Shortage Is Particularly High-Risk

Most drug shortages cause inconvenience. An MMF shortage can cause organ rejection. The clinical stakes differ by patient population:

• Solid organ transplant recipients: MMF is a cornerstone of triple immunosuppression (CNI + MMF + corticosteroid). Any gap in this regimen creates a window for acute cellular or antibody-mediated rejection. Even brief interruptions carry measurable risk, particularly in the early post-transplant period.
• Lupus nephritis patients: MMF is the first-line maintenance agent for lupus nephritis (Class III/IV) per ACR and EULAR guidelines. Interruption can trigger renal flares that may require IV methylprednisolone or rescue cytotoxic therapy.
• Systemic autoimmune conditions (vasculitis, myasthenia gravis, pemphigus): Lower immediate risk than transplant, but disease flares after MMF discontinuation are well-documented and may require escalation of therapy.

Therapeutic Options: A Clinical Decision Framework

Before considering a therapeutic switch, exhaust alternative sourcing options (see below). When a switch is necessary, consider the following:

Option 1: Switch to Brand-Name CellCept or a Different Generic Manufacturer

First-line approach: prescribe brand-name CellCept (Genentech) if any generic manufacturer is short. Brand-name product is generally more reliably stocked. The Genentech CellCept savings card allows eligible commercially-insured patients to pay as low as $15/month. If cost is a barrier for uninsured patients, point them to the PAN Foundation patient assistance program.

Option 2: Switch to Mycophenolate Sodium (Myfortic)

Mycophenolate sodium (EC-MPS, Myfortic) delivers the same active moiety — mycophenolic acid — as mycophenolate mofetil. The enteric-coated formulation delays release to the small intestine, which may reduce upper GI side effects in some patients. Dose conversion: mycophenolate mofetil 2 g/day is approximately equivalent to mycophenolate sodium 1,440 mg/day (EC-MPS 720 mg twice daily). Prescribe the new formulation explicitly — do not rely on pharmacy substitution without a written dose conversion.

Option 3: Switch to Azathioprine

Azathioprine is the most evidence-based therapeutic alternative across all MMF indications. Key considerations:

• TPMT/NUDT15 genotyping: Essential before or shortly after initiation. Patients with low TPMT activity are at risk for life-threatening myelosuppression at standard doses.
• Transplant dosing: Typically 1-3 mg/kg/day; lower end in renal impairment.
• Lupus nephritis: Acceptable maintenance alternative, though meta-analyses suggest MMF has superior efficacy in some patient populations, particularly Black and Hispanic patients. In one pivotal RCT, MMF was superior to azathioprine for time to treatment failure (HR 0.44; P=0.003).
• Interactions: Allopurinol significantly increases 6-MP levels — reduce azathioprine dose by 50-75% if co-prescribed.

Monitoring Recommendations During Any Transition

Regardless of which alternative is chosen, increase monitoring intensity during and after any regimen change:

• CBC with differential: weekly for first 4 weeks after switch, then monthly
• Renal function (creatinine, BUN): especially important in transplant patients
• Transplant patients: consider increased surveillance biopsies if extended MMF interruption occurred
• Lupus nephritis patients: urinalysis, urine protein-to-creatinine ratio, complement levels, anti-dsDNA antibody titers

Operational Steps for Transplant Centers and Rheumatology Practices

1. Audit your patient panel. Identify all patients currently prescribed mycophenolate mofetil and flag any who have had recent fill delays or are due for refill within the next 30 days.
2. Create a standing shortage protocol. Pre-authorize your clinical staff or transplant coordinators to switch patients to brand-name CellCept or Myfortic (with dose conversion) without requiring a physician appointment each time.
3. Partner with a specialty pharmacy. Specialty pharmacies (Amber Specialty, AllianceRx Walgreens, CVS Specialty) maintain dedicated immunosuppressant stock and can alert your practice when supply issues arise.
4. Proactively communicate with patients. Send a proactive message to MMF-dependent patients explaining the shortage, giving them steps to take, and telling them to contact the practice immediately if they cannot fill their prescription. Patient access tools like medfinder can help patients locate stock at nearby pharmacies without burdening your care team.
5. Consider 90-day supplies. Where clinically and insurably appropriate, prescribe 90-day supplies to reduce refill frequency and supply gap risk.

Resources for Providers

• ASHP Drug Shortage Database: Monitor for current status and alternative manufacturers
• medfinder for Providers: Help your patients find their medication in stock at nearby pharmacies
• FDA MedWatch Drug Shortage Database: Official shortage status and FDA communications

For the complementary patient-focused article, see: Mycophenolate Mofetil Shortage Update: What Patients Need to Know in 2026.